GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Price-to-Free-Cash-Flow

Pharma Equity Group A/S (OCSE:PEG) Price-to-Free-Cash-Flow : N/A (As of Jun. 02, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Price-to-Free-Cash-Flow?

As of today (2024-06-02), Pharma Equity Group A/S's share price is kr0.248. Pharma Equity Group A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was kr-0.02. Hence, Pharma Equity Group A/S's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Pharma Equity Group A/S's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, Pharma Equity Group A/S's highest Price-to-Free-Cash-Flow Ratio was 1.62. The lowest was 0.03. And the median was 0.28.

OCSE:PEG's Price-to-Free-Cash-Flow is not ranked *
in the Biotechnology industry.
Industry Median: 30.975
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Pharma Equity Group A/S's Free Cash Flow per Share for the three months ended in Mar. 2024 was kr-0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was kr-0.02.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 63.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 32.90% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 39.20% per year.

During the past 13 years, Pharma Equity Group A/S's highest 3-Year average Free Cash Flow per Share Growth Rate was 86.50% per year. The lowest was -92.20% per year. And the median was 32.40% per year.


Pharma Equity Group A/S Price-to-Free-Cash-Flow Historical Data

The historical data trend for Pharma Equity Group A/S's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Price-to-Free-Cash-Flow Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Price-to-Free-Cash-Flow

For the Biotechnology subindustry, Pharma Equity Group A/S's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Price-to-Free-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Price-to-Free-Cash-Flow falls into.



Pharma Equity Group A/S Price-to-Free-Cash-Flow Calculation

Pharma Equity Group A/S's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.248/-0.02
=N/A

Pharma Equity Group A/S's Share Price of today is kr0.248.
Pharma Equity Group A/S's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.02.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Pharma Equity Group A/S  (OCSE:PEG) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Pharma Equity Group A/S Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.